期刊文献+

厄洛替尼治疗非小细胞肺癌的机制、现状与展望 被引量:3

The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer
下载PDF
导出
摘要 概述厄洛替尼治疗非小细胞肺癌的作用机制、临床应用现状及常见、严重不良反应,指出其在非小细胞肺癌治疗中的应用前景。 By overviewing the mechanism ,clinical application and adverse drug reaction(ADR) of erlotinib, to indicate its perspective in the therapy of non-small cell lung cancer.
作者 赵燕 张茹
出处 《中国药物警戒》 2010年第10期617-619,共3页 Chinese Journal of Pharmacovigilance
关键词 厄洛替尼 非小细胞肺癌 机制 展望 erlotinib non-small cell lung cancer(NSCLC) mechanism perspective
  • 相关文献

参考文献12

  • 1American Cancer Society.Cancer Facts and Figures 2008[EB/OL].2009-07-13[2010-06-25].http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
  • 2World Health Organization.Fact Sheet No.310[EB/OL].2009-07-13[2010-06-25].http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
  • 3Postmus P E,Smit E F.Chemotherapy for brain metastases of lung cancer:a Review[J].Ann Oncol,1999,10(7):753-759.
  • 4Endelsohn J,Baselga J.Status of the epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].J Clin Oncol,2003,21(14):2787-2799.
  • 5Herbst R S,Shin D M.Monoclonal antibodies to target epidermal growth factor receptor-positive tumors:a new paradigm for cancer therapy[J].Cancer,2002,94(5):1593-1611.
  • 6Metro G,Finocchiaro G,Cappuzzo F.Anti-cancer therapy with EGFR inhibitors:factors of prognostic and predictive significance[J].Ann Oncol,2006,17(suppl 2):842-845.
  • 7Mok T,Wu Y-L,Thongprasert S,et al.Phase Ⅲ,randomized,open-label,first-line study of gefitinib(G)versus carboplatin/paclitaxel(C/P)in clinically selected patients(pts)with advanced non-small-cell lung cancer(NSCLC)[J].Ann Oncol,2008,19(suppl8):1-4.
  • 8Hirsch F R,Varella-Garcia M,Bunn PA Jr,et al.Epidermal growth factor receptor in non-small-cell lung carcinomas:correlation between gene copy number and protein expression and impact on prognosis[J].J Clin Oncol,2003,21:3798-3807.
  • 9Hirsch F R,Varella-Garcia M,Bunn P A Jr,et al.Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced nonsmall-cell lung cancer[J].J Clin Oncol,2006,24:5034-5042.
  • 10Tsan M S,Sakurada A,Cutz J C,et al.Erlotinib in lung cancer:molecular and clinical predictors of outcome[J].N Engl J Med,2005,353:133-144.

同被引文献22

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部